Looking back at the third quarter, what stands out for me is the remarkable progress we've made across our late stage pipeline and broad inline portfolio. We've seen important positive clinical readouts, regulatory milestones, and record sales performance for several of our key medicines. The consistency of these achievements reflects the breadth and strength of Amgen today and reinforces our confidence in the growth opportunities ahead. Our commercial performance reflects this progress. Product sales grew 8% year over year, and we have 17 products annualizing at more than $1 billion in sales. All six of our key growth drivers deliver double digit growth in the quarter, together growing 27% year over year and now representing more than 70% of product sales. Starting with general medicine, Rapatha delivered $1.1 billion in third quarter sales, growing 37% year over year. Rapatha's momentum continues to accelerate with U.S. average weekly new to brand prescriptions increasing over 60% compared with the prior year. This growth is supported by increased urgency to treat in both secondary prevention and high risk primary prevention patients. With the landmark Basalea CB results, Rapatha is now the only PCS-K9 inhibitor with phase 3 cardiovascular outcomes evidence in both primary and secondary prevention. We're seeing deepening conviction and adoption among cardiologists and accelerating use in primary care. ? The updated ACC and AHA guidelines reinforce earlier, more intensive LDL cholesterol lowering and support the use of PCS-K9 inhibitors without requiring prior treatment with the zetamide. The new guidelines, supported by Rapatha's differentiated outcomes data, strengthen clinical conviction that Rappatha should be the first choice when additional LDL cholesterol lowering is needed beyond STANS. This year alone, we expect more than 3 million additional patients globally to start treatment with Rapatha. With an estimated 100 million patients worldwide still above their LDL-C goals, we are only beginning to address the significant unmet ? need, giving us confidence in Rapatha's growth potential into the 2030s. Avenity sales increased 39% in the third quarter to $751 million, building on 38% year-over-year growth in the previous quarter. In the United States, robust patient demand continues to drive momentum, supported by an expanding prescriber base and deeper adoption among treating physicians. We're increasing investment to expand our reach among physicians and to help more patients access treatment with avenity. The opportunity remains significant, particularly when we consider the devastating consequences of osteoporotic fractures. One in two patients who experience a hip fracture do not regain their prefracture mobility. This reinforces the importance of earlier intervention and our conviction ? in avenity's potential to help more women at very high fracture risk, including those who have not yet experienced a fracture. In Japan, Avenity maintains leadership in the bone builder category with nearly 60% volume share. Updated treatment guidelines and increasing use among treatment naive patients are supporting continued growth and reinforcing Avenity's important role in osteoporosis ? care. Moving to inflammation, ? test buyer sales grew 43% year over year, reaching $538 million, driven by strong demand and severe uncontrolled asthma. Test buyer's growth continues to outperform the severe uncontrolled asthma market, with U.S. new to brand prescriptions growing 15% year over year versus 3% market growth. Test buyers achieved 34% new to brand prescription share among allergists in the US and continues to gain share among pulmonologists with substantial room for further adoption. The consistent flow of strong clinical data continues to reinforce test buyers' differentiated efficacy across inflammatory diseases. Phase three results in chronic rhinosinusitis with nasal bulbs demonstrated improvements in disease control and a reduction in the need for surgery. More recently, positive phase three results in neosinophilic esophagitis or EOE demonstrated meaningful improvements in key measures of disease activity and symptoms, highlighting another potential new opportunity for Test buyer to help more patients. Turning to rare disease, this portfolio grew 21% year over year to $1.6 billion, reflecting continued momentum from additional indications and disciplined execution of international expansion. We see opportunity to extend the reach of these treatments, improve outcomes for patients, and sustain meaningful growth well into the next decade. ? The PLISNA sales increased 191% year over year to $451 million in the third quarter, driven by strong patient demand across all approved indications. UPLISNA offers a highly differentiated clinical profile, combining outstanding efficacy that resonates with physicians and convenient twice-yearly dosing that benefits patients. This profile is supported by broad pair coverage ? and AMGEN's comprehensive patient support services, helping physicians initiate treatment and support continuity of care. ? In the US, the PLISNA is demonstrating significant growth in generalized myocania gravis or GMG, with new and continuing patients increasing 45% quarter over quarter. Adoption is expanding among both biologic naive patients and those transitioning from other therapies, reinforcing our confidence in the PLISNA's potential to establish market leadership in this category. In IgG4-related disease, long-term follow-up data from the Phase III mitigate study continued to reinforce Uplizna's durable efficacy profile. All patients who continued treatment with Uplizna remained flair-free through the first year of the open label extension, with more than 70% achieving complete remission without glucocorticoids. These durable results, together with growing disease awareness and improved diagnosis, support our confidence in Uplizna's potential to help many more patients.
Passages & reports (33) 4:17 Looking back at the third quarter, what stands out for me is the remarkable progress we've… Report 4:37 the breadth and strength of Amgen today and reinforces our confidence in the growth opport… Report 4:56 quarter, together growing 27% year over year and now representing more than 70% of product… Report 5:16 weekly new to brand prescriptions increasing over 60% compared with the prior year. This g… Report 5:36 cardiovascular outcomes evidence in both primary and secondary prevention. We're seeing de… Report 5:48 The Report 5:49 updated ACC and AHA guidelines reinforce earlier, more intensive LDL cholesterol lowering … Report 6:09 be the first choice when additional LDL cholesterol lowering is needed beyond STANS. This … Report 6:28 address the significant unmet Report 6:31 need, Report 6:31 giving us confidence in Rapatha's growth potential into the 2030s. Avenity sales increased… Report 6:51 supported by an expanding prescriber base and deeper adoption among treating physicians. W… Report 7:11 patients who experience a hip fracture do not regain their prefracture mobility. This rein… Report 7:20 in Report 7:20 avenity's potential to help more women at very high fracture risk, including those who hav… Report 7:40 naive patients are supporting continued growth and reinforcing Avenity's important role in… Report 7:47 care. Report 7:48 Moving to inflammation, Report 7:49 test Report 7:50 buyer sales grew 43% year over year, reaching $538 million, driven by strong demand and se… Report 8:10 market growth. Test buyers achieved 34% new to brand prescription share among allergists i… Report 8:29 differentiated efficacy across inflammatory diseases. Phase three results in chronic rhino… Report 8:49 meaningful improvements in key measures of disease activity and symptoms, highlighting ano… Report 9:09 indications and disciplined execution of international expansion. We see opportunity to ex… Report 9:23 The Report 9:23 PLISNA sales increased 191% year over year to $451 million in the third quarter, driven by… Report 9:43 with physicians and convenient twice-yearly dosing that benefits patients. This profile is… Report 9:51 and Report 9:51 AMGEN's comprehensive patient support services, helping physicians initiate treatment and … Report 10:00 In Report 10:01 the US, the PLISNA is demonstrating significant growth in generalized myocania gravis or G… Report 10:20 confidence in the PLISNA's potential to establish market leadership in this category. In I… Report 10:40 flair-free through the first year of the open label extension, with more than 70% achievin… Report